On September 10, 2024 ICE Bioscience and NanoTemper Technologies reported an exciting new partnership to establish a Biophysical Joint Innovation Platform (Press release, ICE Bioscience, SEP 10, 2024, View Source;catname=icenews [SID1234647432]). The signing and unveiling ceremony took place at ICE Bioscience’s headquarters in Beijing, with senior leadership from both companies in attendance, including Dr. TJ Bing, Senior Vice President of ICE Bioscience, Dr. Qiang Xia, Vice President of ICE Bioscience, and Barrett Lee, NanoTemper’s Head of APAC Commercial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Bing and Mr. Lee officially signed the cooperation agreement and jointly unveiled the new platform, marking the beginning of an innovative collaboration aimed at advancing biophysics research and applications in drug discovery.

During the event, Dr. Bing welcomed the NanoTemper team and emphasized ICE Bioscience’s commitment to innovation and technology in drug discovery. He highlighted the company’s significant investment in R&D and the strategic alignment of NanoTemper’s Spectral Shift technology with ICE’s goals of exploring new targets, new technologies, and new assays.

Barrett Lee expressed NanoTemper’s appreciation for ICE Bioscience’s trust and enthusiasm for bringing cutting-edge technologies to global researchers. He shared his confidence that this partnership would support ICE Bioscience in becoming a leader in binding affinities and protein stability services, providing essential tools for high-throughput screening.

Following the unveiling, ICE Vice President Xia Qiang led the NanoTemper representatives on a tour of the newly established innovation platform, showcasing the company’s advancements in biophysical assays and outlining future objectives for the platform.